Mike Burgess

Dr. Michael Burgess has served as President of Research and Development at Turnstone Biologics since October 2017. Mike is a recognized senior leader in the pharmaceutical industry with over 20 years of drug research and development experience. Prior to joining Turnstone, he led the strategy and execution of translational medicine, early-stage clinical trials, and clinical pharmacology across all therapeutic areas, including oncology at Bristol-Myers Squibb. Prior to this at Roche Pharmaceuticals, Mike held several senior leadership positions, including acting global head of Roche Pharma Research and Early Development (pRED) and Senior Vice President and Global Head of Oncology Research and Early Development. Before joining Roche, Mike spent 7 years at Lilly working on early-stage oncology trials. Mike received his medical degree (M.B., Ch.B.) and a Ph.D. in molecular biology from the University of Bristol, UK, and spent 10 years as a practicing physician in pediatrics and pediatric oncology.